Loading clinical trials...
Loading clinical trials...
AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this ...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
AVM Biotechnology Inc
NCT07249528 · Non-hodgkin Lymphoma, Multiple Myeloma
NCT05268614 · Oropharyngeal Squamous Cell Carcinoma
NCT07463573 · Esophageal Squamous Cell Carcinoma (ESCC)
NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more
NCT07209189 · Head and Neck Cancer, Squamous Cell Carcinoma, and more
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions